𝗧𝗵𝗶𝗻𝗸𝙁𝘼𝙎𝙏. In what threatens to be yet another PR problem for pharma, we once again see “Pharma Bro” Martin Shkreli in the news. Less than a year after being released from prison, and with a lifetime ban on “working in the pharmaceutical industry,” we see him founding a company, “Druglike,” that claims to be a “platform for democratizing the access, costs and rewards of early-stage drug discovery.” Not really a drug company, he says. The FTC is not so sure.
In any event, the man responsible for raising the price of Daraprim, used to treat AIDS and Cancer, from $17.50 to $750 per tablet during his time as CEO at Turing Pharmaceuticals, and as a result becoming “one of the most hated men in America,” who even inspired the Shkreli Awards, which call out the most dysfunctional players in healthcare, is not likely to be a PR asset for the pharmaceutical industry. Keep your eyes on this at: https://bit.ly/3IGk0US
To view more ThinkFast posts: https://bit.ly/3Si5GFk